Consultation of the e-posters selected by the iMig Scientific Committee, whose themes are as follows (click on the chosen theme):

PO-012CHEK1 and BAP1 combination as a potential prognostic biomarker for pleural mesothelioma, PANOU Vasiliki.

PO-013 – Prognostic impact of inflammation in malignant pleural mesothelioma: large-scale analysis of a single center cohort, FOURNEL Ludovic.

PO-024 – Transcriptomic profiling identifies a 6-gene mesothelioma-specific prognostic gene signature that predicts survival, FISHER Scott Andrew.

PO-031 – VEGFR2 /CD34 expression associated with longer survival in patients with malignant pleural mesothelioma (MPM) in the IFCT-GFPC-0701 MAPS phase 3 trial, ZALCMAN Gérard.

PO-034 – In silico analysis enabled the identification of new putative markers for MPM, BISCEGLIA Luisa.

PO-042 Inherited Predisposition to Mesothelioma: BAP1 Syndrome and other HRR Defects, SCULCO Marika.

PO-049Developing a community-driven knowledge based molecular pathway for Malignant Pleural Mesothelioma, MARTENS Marvin.

PO-053 – Effusion cytokine profile as a biomarker of BAP1 loss in pleural mesothelioma, NASH Alistair.

PO-057Prediction of Resistance to Chemotherapy using Somatic Copy Number Variation in Mesothelioma: Results of a multi-centre retrospective cohort study, BLYTH Kevin.

PO-058 – Transcriptomic Characterization of Extracellular Vesicles Secreted By Pleural Mesothelioma Reveals a Clinically Relevant Gene Signature, KRAFT Agnieszka.

PO-059 – Genome-wide DNA methylation analysis reveals the existence of many differentially methylated CpG sites with biomarker potential in the MPM epigenome, DE MEULENAERE Nele.

PO-066 – Exhaled breath analysis predicts treatment response in malignant pleural mesothelioma patients, HEIRWEGH Ellen.

PO-068 – Low Ki-67 Positive Index is a Prognostic Factor for Better Survival Outcomes of Patients Treated with Intracavitary Cisplatin-Fibrin, MEERANG Mayura.

PO-171 – Monitoring Serum CA-125 and Mesothelin Levels After Pleurectomy Decortication in Pleural Mesothelioma, SADEK Ahmed.

PO-082A serum biomarkers panel evaluation revealed a potential diagnostic role for IL-6, HGF, E-SELECTIN, and OPN in malignant pleural mesothelioma, SILVESTRI Roberto.

PO-083Diverging Expression of CHK1 in Malignant Mesothelioma Treated with Radio therapy: A Case Report, ASGHARI BIRBANEH Azadeh.

PO-087PD-L1 Expression as a Prognostic Factor of Overall Survival in Patients with Malignant Pleural Mesothelioma, BARBOLINA Tatyana.

PO-088 – Primary cilium BBSome gene expression profile during the exposure of benign mesothelial cells to pleural effusion fluid of different etiologies in 3D, ZAROGIANNIS Sotirios.

PO-091 – New immunohistochemical markers for pleural mesothelioma subtyping, DI STEFANO Iose.

PO-093 – MACADAM (MesotheliomA ClinicAl DAta platforM), an advanced clinical data platform for mesothelioma investigation and improvement of clinical pathways, GROSSO Federica.

PO-094 – Type 3 collagen, a potential new marker for the differential diagnosis of malignant pleural mesothelioma associated with overall patient survival, BLANQUART Christophe.

PO-095 – CD27-IgD- B cells might portray an exhausted B cell phenotype resulting in lack of response to checkpoint inhibitor treatment in pleural mesothelioma, BELDERBOS Robert Anton.

PO-100BAP1, Wilms’ tumor 1, and calretinin in predicting survival and response to chemotherapy in patients with malignant pleural mesothelioma, METINTAS Muzaffer.

PO-102A Danish and a Turkish cohort of patients with pleural mesothelioma treated with pemetrexedpemetrexed-based chemotherapy: differences, similarities and prognostic factors, PANOU Vasiliki.

PO-105 – A Breathomics Based Approach To Improve Mesothelioma Diagnosis, BONSALL Sam.

PO-109 – Serial serum mesothelin (SM) as a biomarker for disease progression and mortality in pleural mesothelioma (PM), LYNCH Geraldine.

PO-111 – Defining a new diagnostic biomarker panel for malignant pleural mesothelioma using a novel proteomic technique, SCHILLEBEECKX Eline.

PO-112 – Krebs von den Lungen 6 (KL-6) is a potential pleural effusion based diagnostic biomarker in pleural mesothelioma, BALAZS Hegedüs.

PO-117 – Clinicopathologic characteristics of adolescent and young adult (AYA) patients with mesothelioma, MITCHELL Owen.

PO-118 Circulating biomarkers in abestos-exposed individuals and mesothelioma patients, WU Licun.

PO-119 – Prognostic Relevance of BAP1 Gene Mutational Status in Patients with Pleural, Peritoneal, and Bicavitary Mesothelioma, HERMINA Andrew.

PO-120 – Primary cilium (PC) associated BBS7 gene is differentially regulated in response to osmotic stress and depending on 2D or 3D culture model, ZAROGIANNIS Sotirios.

PO-151 – BAP1-related tumor predisposition syndrome (BAP1-TPDS) in a patient with diagnosis of choroid melanoma, peritoneal mesothelioma and cholangiocarcinoma, MUTTI Luciano.

PO-164Proteomics markers as potential tools for Pleural Mesothelioma risk assessment, JALIS HERMAN Elton.

PO-001 – Implementation of the diagnostic algorithm for the cytological diagnosis of pleural mesothelioma, ALI Greta.

PO-002 – Genetic Alterations and Clinical Parameters Affect Patient Survival and Programmed Death Ligand 1 (PD-L1) Expression in Mesothelioma, ZHU Allen.

PO-004 – Profiling of microRNAs from Serum and Pleural Effusion derived extracellular vesicles of Pleural Mesothelioma in a retrospective cohort, CASALONE Elisabetta.

PO-021 – The Scottish Mesothelioma Network: Impact of a national multidisciplinary team on Overall Survival in Malignant Pleural Mesothelioma, TATE Matthew.

PO-037Proposed Guidelines for Pathologic Diagnosis of Mesothelioma: 2023 Update of Consensus Statement from the International Mesothelioma Interest Group, HUSAIN Aliya.


PO-052 – Assessment of Exhaled Volatile Organic Compounds as Biomarkers for Erionite Exposure: A Comparative Study in Tuzköy Village, Cappadocia, Turkey, EMRI Salih.

PO-060 – Exploring the clinical and pathological features associated with long survival in pleural mesothelioma (PM) patients, LYNCH Geraldine.

PO-062 – Identification of genes associated with mesothelioma patient survival using HTG transcriptome analysis, DAMIOLA Francesca.

PO-085 – Significance of BAP1 loss and MTAP loss in biopsy specimens of early-stage malignant pleural mesothelioma, ANDO Kohei.

PO-097 – TP53 alteration is significantly more prevalent in epithelioid mesothelioma with higher nuclear grade, nuclear atypia, and mitotic count, MUELLER Jeffrey.

PO-098 – Stemness-related markers in diffuse malignant mesothelioma of the pleura, NAKASHIMA Yasuhiro.

PO-107 – Usefulness of US guided pleural biopsy in the diagnostic workflow of pleural mesothelioma, ASSIE Jean-Baptiste.

PO-123 – Diagnostic accuracy of ultrasound-guided pleural biopsy for the diagnosis of malignant pleural mesothelioma, SELMANI Mohamed Redha.

PO-124 – Medical thoracoscopy: contribution in the diagnosis of pleural pathologies, DABOUSSI Selsabil.

PO-125 – Pleural symphysis through medical thoracoscopy: efficiency and safety, DABOUSSI Selsabil.

PO-084 Optimising radiotracer production and in vivo PET CT protocols to track PD L1 distribution and expression in mesothelioma, HOANG Tracy.

PO-104 – Extent of discordant therapeutic response classification in malignant pleural mesothelioma by expert readers: A multicentre retrospective cohort study, BLYTH Kevin.

PO-106 – Nodal predominant pattern of failure in malignant pleural mesothelioma receiving immunotherapy, KATZ Sharyn.

PO-110 – Malignant pleural mesothelioma mimicking a complex parapneumonic effusion: a case report, KATZ Sharyn.

PO-113 – Diagnostic Value and Consistency of ADC and Dynamic Contrast MR Examination in Differentiating Epitheloid and Non-Epitheloid Subtypes in Malignant Ple, AYDIN Nevin.

PO-114 – Back-translation of human MRI endpoints of Mesothelioma to a Genetically Defined Mouse Model, JAYASEKERA Geeshath.

PO-138Artificial Intelligence for the Segmentation of Mesothelioma: Analysis of Performance Based on Computer Probability Outputs (CALGB 30901, Alliance), SHENOUDA Mena.

PO-130Facilitators of and barriers to continuity with GPs in primary palliative cancer care: A mixed methods systematic review, COUCHMAN Emilie.

PO-131Facilitators and barriers to early diagnosis of malignant mesothelioma (FILMM): A qualitative study of patient experiences living in England, OVIASU Osaretin.

PO-132 – Mental health and well-being living with mesothelioma – impacts and interventions: qualitative findings from a UK study, TOD Angela.

PO-135 From research to practice: improving early stage engagement with palliative care for patients and families living with mesothelioma, HARGREAVES Sarah.

PO-139 – Snapshot audit of Patient Caseload at Mesothelioma Specialist Centre and the role of the Mesothelioma UK Nurse specialist in managing these patients, NELSON Louise.

PO-142Snapshot audit of the Mesothelioma Patient Caseload at the University Hospitals of Leicester (UHL) and the role of the Mesothelioma UK Nurse Specialists, NELSON Louise.

PO-161 – Improving Research Access for Mesothelioma Patients (IRAMP), BOLTON Simon Paul.

PO-165Rethinking continuity in primary care for people with mesothelioma, COUCHMAN Emilie.

PO-167 – Anorexia was associated with higher nodal stage in malignant pleural mesothelioma but not with survival outcomes, AZIZ Hala.

PO-170Provision of Professional & Peer support for Young people living with Mesothelioma, MORTON Julie.

PO-171Second- and third-line chemotherapy in the treatment of malignant pleural mesothelioma, AK Güntülü.

PO-172 – Spontaneous pneumothorax as a presentation of malignant pleural mesothelioma, TAYLOR Paul.

PO-173 – A single-center, retrospective study of dysphagia in patients with pleural mesothelioma, MITCHELL Owen.

PO-174 – Perceptions and measurements of dyspnea and quality of life experienced by pleural mesothelioma patients before and after lung-sparing surgery, CULLIGAN Melissa.

PO-175 – 10-year survival with non-resectable Pleural Mesothelioma T2N3M0 on platinum and pemetrexed alone with 4 times re-induction – a case report, HORSTED Cecilia Bech.

PO-176 – Mesothelioma and Nutrition – Exploring Attitudes and Experiences of Healthcare Professionals working in a Hospital within a high incidence area of the, TAYLOR Leah.

PO-005 – Salvage surgery after immunotherapy for unresectable malignant pleural mesothelioma: Case series, TAKEGAHARA Kyoshiro.

PO-009 – Prophylactic Pedicle Latissimus Flap with Pleurectomy and Decortication for Malignant Pleural Mesothelioma, KUCKELMAN John.

PO-010 – A novel surgical approach to improve visceral decortication and aerostasis after extended pleurectomy/decortication for malignant pleural mesothelioma, PROVOOST An-Lies.

PO-011 – Longterm-Outcome of mesothelioma patients treated with intracavitary cisplatin-fibrin therapy after surgery – results of a phase I/II clinical trial, THEISEN-LAUK Olivia.

PO-035 Improving Malignant Pleural Mesothelioma Outcomes Through Regionalization & Multidisciplinary Care, TUPPER Haley.

PO-041 – Final results of MesoPDT trial: intrapleural photodynamic therapy plus pleurectomy/decortication then chemotherapy in pleural mesothelioma patients, SCHERPEREEL Arnaud.

PO-050 – Long-term survival (8 years+) in patients with R0-R1 resected pleural mesothelioma, SCHUANG LÜ Maya Jeje.

PO-056 – Clinical characteristics of long-term survivors of malignant pleural mesothelioma, HASHIMOTO Masaki.

PO-064 – CDKN2A expression determines survival after sub-ablative irradiation and surgery in pleural mesothelioma – Long-term results from the SMART trial, DE PERROT Marc.

PO-079 – Clinical characteristics and outcomes of patients with well differentiated papillary peritoneal mesothelial tumors, AGUIRRE Nicole.

PO-080Median survival time of female malignant pleural mesothelioma treated by multimodality therapy with extrapleural pneumonectomy reaches 70 months, OKABE Kazunori.

PO-081 – Risk factors influencing postoperative pleural empyema in patients with pleural mesothelioma after surgery – a retrospective single center analysis, THEISEN-LAUK Olivia.

PO-086 – Stromal Ki67 has a predictive value in determining outcomes following extended pleurectomy/decortication, KUDZAYI Kutywayo.

PO-099 – Outcomes of Pleurectomy Decortication in Sarcomatoid Mesothelioma, LAPIDOT Moshe.

PO-101 – Outcomes of Neoadjuvant Therapy in Pleural Mesothelioma Patients Undergoing Pleurectomy/Decortication: A Single Center Experience, KAHYA Yusuf.

PO-115 – Outcome of extended pleural decortication in combined modality treatment for malignant pleural mesothelioma: a 3-year single-centre experience, PROVOOST An-Lies.

PO-116 – Salvage Surgery Following Progression on Immune Check Point inhibitors for Malignant Pleural Mesothelioma, KUTYWAYO Kudzayi.

PO-122Effectiveness of immune checkpoint inhibitor and radiotherapy in multimodality therapy for Malignant Pleural Mesothelioma, MOROHOSHI Takao.

PO-169 – Focal radiotherapy for oligo-progressive pleural mesothelioma: fine-tuning the optimal doses, CERESOLI Giovani Luca.

PO-025 – Octogenarians and survival outcomes in malignant pleural mesothelioma: Analysis of SEER database, RAHOUMA Mohamed.

PO-040 – The Impact of Military and Civilian Health Partnership in Raising Awareness of Asbestos Exposure in Military Personnel and Veterans, MOYLAN Anne.

PO-092Under declaration of Mesothelioma in France to the FIVA, LALLIARD Sabine.

PO-103 – Mesothelioma in Cyprus 1999-2019, a descriptive analysis, Oluf Dimitri Røe.

PO-108 – Prior radiotherapy in mesothelioma patients: an observational study, TAYLOR Paul.

PO-126Spation analysis of the relationship between the density of the environmentally abestos-exposed population and the incidence of Mesothelioma in rural areas, METINTAS Selma.

PO-127 – Treatment patterns and overall survival for patients with malignant pleural mesothelioma in Denmark between 2011–2018: a population-based cohort study, PLUMMER Alison.

PO-136 – A new system of mesothelioma epidemiological surveillance in France, GRANGE Dorothée.

PO-140Shipbreaking: Creating Accountability A Follow up to our presentation at iMig 2021, KAZAN Steven.

PO-143Sociodemographic and Quality of Life Analysis of a Cohort of Malignant Pleural Mesothelioma Patients at the Toronto Mesothelioma Program, SHARIATI Sara.

PO-145Patients’ Rights to Compensation from United States Asbestos Bankruptcy Trust Funds Another Update, KAZAN Steven.

PO-146A Review of the Literature on Pericardial Malignant Mesothelioma: A Follow-up, KAZAN Steven.

PO-148 Evading Liability. Evading Responsibility. Dancing with Saint-Gobain, KAZAN Steven.

PO-149Medical privacy, genetic testing, and informed consent in abestos litigation, KAZAN Steven.

PO-150Mesothelioma patient and carer experience: a research prioritisation exercice, TAYLOR Bethany.

PO-003 – Vascular-remodelling radiotherapy increases the response rate to combined anti-PD-1 and anti-CTLA-4 immunotherapy, COOK Alistair.

PO-007 – Dendritic cell therapy combined with extended-Pleurectomy/Decortication in resectable mesothelioma (ENSURE trial): results first patient, BELDERBOS Robert Anton.

PO-008 – Phenotype and functional status of tumour natural killer (NK) cells in malignant pleural mesothelioma (MPM): a pilot study, KLAMPATSA Astero.

PO-016 – Ipilimumab plus nivolumab for advanced mesothelioma: implementation into clinical practice, HO Cheryl.

PO-020 Nivolumab in pretreated Pleural Mesothelioma (PM): results of a retrospective study of patients treated in second or further line in Italy, GROSSO Federica.

PO-023 – Radiotherapy modulates key immune markers on mesothelioma cells in a manner that is dose- and time- dependent, and variable between individuals, CHANG Faith.

PO-028 – Nivolumab and ipilimumab in the real-world setting in patients with unresectable mesothelioma, HOFMAN Maaike.

PO-029 – Synergistic Effects of Combining Immune Checkpoint Inhibition and Anti-Angiogenic Therapy in the Treatment of Malignant Pleural Mesothelioma, ROVERS Sophie.

PO-032 – Development of magneto-fluorescent nanoassemblies targeted to mesothelin, BRIOLAY Tina.

PO-033 – Development of new affinity molecules for the targeting of mesothelin, BRIOLAY Tina.

PO-038 – Tumor immune microenvironment associates with treatment response to Immune Checkpoint Therapy (ICT) in mesothelioma, LI Huihua.

PO-039 – Metronomic chemotherapy improves effectiveness of pleural mesothelioma immunotherapy, FONTAINE Alexis.

PO-044 – Impairment of measles virus oncolytic activity by healthy cells depends on the type of interferon pathway defect in mesothelioma cells, CHATELAIN Camille.

PO-055 – Two cases of hyperprogressive diseases in pleural mesothelioma with immune checkpoint inhibitors, ASSIE Jean Baptiste.

PO-067 – IMMUNOTHERAPY PLEURAL 5-ALA PDT « IMPALA » feasibility trial: intrapleural PhotoDynamic Therapy by VATS then Nivolumab in relapsing Pleural Mesothelioma, SCHERPEREEL Arnaud.

PO-075 – Prodrug Activator Gene Therapy Using Retroviral Replicating Vectors and Mesenchymal Stem Cells in an Experimental Model of Human Malignant Mesothelioma, KUBO Shuji.

PO-077 – Characteristics of gene expressions in peripheral blood lymphocytes in a case of malignant pleural mesothelioma with partial response to nivolumab, NISHIMURA Yasumitsu.

PO-089 – Major therapeutic response with BEVACIZUMAB in eighth-line treatment in a patient with unresectable epithelioid pleural mesothelioma (PM), ALIOUAT Amira.

PO-163 – Immune monitoring in malignant peritoneal mesothelioma patients treated with dendritic cell-based immunotherapy after cytoreductive surgery and HIPEC, WILLEMSEN Marcella.

PO-006 – Single-cell transcriptomic analysis of human pleura reveals stromal heterogeneity and informs in vitro models of mesothelioma, VEALE Niki.

PO-014 – Targeting YB-1 as a therapeutic strategy in pleural mesothelioma, SCHELCH Karin.

PO-017Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of pleural mesotheliomas to CDK4/6 inhibition, PATERNOT Sabine.

PO-018 – Genome-wide copy number analysis identifies AKT as new therapeutic target for malignant pleural mesothelioma, KALLA Claudia.

PO-019 – Primary and hTERT-immortalized mesothelioma-associated fibroblasts and mesothelial cells as new tools for mesothelioma research, GRUSH Michael.

PO-022 – Establishing mesothelioma patient-derived organoid models from malignant pleural effusion, HOCKING Ash.

PO-026Molecular and functional characterization of TEAD family members in pleural mesothelioma, BENNANI ZIATNI Khawla.

PO-027Mesothelin-binding Fn3 for a novel theranostic approach against malignant pleural mesothelioma, PICCARDI Margherita.

PO-030 – Loss of BAP1 influences mesothelioma cellular motility suggesting new therapeutic approaches, TRIPARI Martina.

PO-043 – Genetically Defined Mouse Models of Malignant Pleural Mesothelioma recapitulate human MPM phenotypes and response to therapy, FARAHMAND Pooyeh.

PO-046 – Characterizing the vascularization patterns of mesothelioma tumor nodules in relation to histological subtypes, ILDIKO Kovacs.

PO-047 – Leptospermum extract (QV0) suppresses pleural mesothelioma tumour growth in vitro and in vivo by mitochondrial dysfunction associated apoptosis, SHI Huaikai.

PO-048 – Autophagy-related Gene Signature Associated with Prognosis and Therapeutics in Malignant Pleural Mesothelioma, ZHANG Chengke.

PO-051 – Investigating the potential utility of a WEE1 inhibitor for the treatment of pleural mesothelioma, JOHNSON Ben.

PO-054 – Dysregulated microRNAs contribute to chemotherapy-resistance of pleural mesothelioma, KIRSCHNER Michaela.

PO-061 – Preclinical assessment of potential combination treatments with PARP inhibition for pleural mesothelioma, HEGEDÜS Luca.

PO-063 – Modelling the Photodynamic Effect in 2D versus 3D Cell Cultures of Malignant Mesothelioma, HAYWOOD-SMALL Sarah.

PO-065PD-L1 has cell autonomous functions in mesothelioma and could be an effective target beyond its role in the immune checkpoint, PENTIMALLI Francesca.

PO-069 – Cullin4B Ubiquitin Ligase Regulates TGF-β1 Pathway in Pleural Mesothelioma, MEERANG Mayura.

PO-070IHC expression of VISTA and CD47 in Malignant Pleural Mesothelioma, HERRERA Mercedes.

PO-072 – Comparative proteome analysis of pleural fluid biomarkers taken from mesothelioma patients, non-malignant and malignant lung diseases, ZAHEDI Sara.

PO-074 – Translational development of PLGA-encapsulated disulfiram microparticles for treatment of malignant mesothelioma, KANNAPPAN Vinodh.

PO-076 – Can We Utilize Collagen Receptor uPARAP as a Target for Antibody-Drug Conjugates in Mesothelioma?, CAKILKAYA Pinar.

PO-078 – TGF-beta signaling is associated with in vitro tumor nodule formation and patient outcome in pleural mesothelioma, STOCKHAMMER Paul.

PO-0903D culture as model to study Malignant Pleural Mesothelioma, LAMARCA Andrea.

PO-152 – The role of Exportin-1 (XPO1) in cisplatin-resistant Malignant Pleural Mesothelioma, WALKER Harriet.

PO-153 – Longitudinal Profiling of Fibre-induced Pre-Neoplastic Lesions and Tumours Reveal Early Molecular Changes in Sporadic Pleural Mesothelioma, CABEZA Zacarias.

PO-154 – Molecular Profiling of Asbestos-induced Sporadic Pleural Mesothelioma Development: a role for Epigenetic Mechanisms in Disease Progression, CABEZA Zacarias.

PO-155 – BAP1 loss in epithelioid mesothelioma is associated with elevated ASS1 expression and resistance to pegylated arginine deiminase, COULSON Judy.

PO-156 – An update regarding the Meso-ORIGINS study: part of the PREDICT-Meso International Accelerator, BLYTH Kevin.

PO-157 – Long-Fibre Carbon Nanotubes induce Malignant Pleural Mesothelioma in the MexTAg Transgenic Mouse Model, replicating Asbestos-induced Mesothelioma, MACFARLANE Marion.

PO-158 – Developing the chick chorioallantoic (CAM) xenograft model for the evaluation of new therapies for malignant pleural mesothelioma, BARNETT Sarah.

PO-159 – BAG2, MDK and MAD2L1 overexpressed genes in malignant pleural mesothelioma cells as selected targets for novel therapies, LANDI Stefano.

PO-160 – A novel therapeutic combination strategy for BAP1 mutant mesothelioma, LANDMAN Nick.

PO-162Signaling pathways analysis highlight YAP and TAZ contribution in pleural mesothelioma, ARNOULD Maya.

PO-168 – Patient-Derived Organoid of Malignant Mesothelioma for personalized Cancer Therapy, VOLPINI Luca.

PO-036 – Prevention of skin reactions related to Tumor Treating Fields (TTFields) therapy used concomitantly with chemotherapy in pleural mesothelioma, GROSSO Federica.

PO-073 – Development of the Mesothelioma UK Clinical Trials App: a resource for patients and healthcare professionals, TAYLOR Leah.

PO-096 – Long-term outcomes in two patients with pleural mesothelioma receiving Tumor Treating Fields (TTFields) therapy with pemetrexed and carboplatin, CERESOLI Giovanni Luca.

PO-121 – PEMbrolizumab Plus Lenvatinib In Second And Third Line Pleural MEsotheLiomA Patients: A Single Arm Phase II Study (PEMMELA): second cohort, DE GOOIJER, Cordeline.

PO-128 – The experience of a District General Hospital when recruiting patients from across the region into a national study within a rare cancer, BOLTON Simon.

PO-129 – A randomised phase II trial of Niraparib versus active symptom control in patients with previously treated mesothelioma, HILL Kayleigh.

PO-166 – Hemi-thoracic Irradiation with Proton Therapy in Malignant Pleural Mesothelioma (HIT-Meso), HILEY Crispin.

PO-134Experiences of care and variability in patient pathways in peritoneal mesothelioma – qualitative findings from a UK study, WESTBROOK Samantha.

PO-141 – First success of immunotherapy to control a peritoneal mesothelioma affecting a patient with familial Mediterranean fever, POCARD Marc.

PO-144 – Treatment outcome in a 10-years cohort of Mesothelioma Tunica Vaginalis Testis in Denmark, SORENSEN Jens Benn.

PO-133The Changing Mesothelioma Patient Profile: implications for clinical practice and nursing care, TOD Angela.

PO-137Experience of caring for people with Mesothelioma of the Tunica Vaginalis, DARLISON Liz.

PO-147 – Achieving Equity for Mesothelioma Patients in Wales: establishing an all-Wales national Mesothelioma network, MORGAN Sarah.